title: No seroconversions among steady sex partners of methadone-maintained HIV-1-seropositive injecting drug users in New York City.
abstract: OBJECTIVE
  To assess the incidence of heterosexual HIV-1 transmission from seropositive methadone-maintained injecting drug users (IDU) to their seronegative, non-IDU steady sex partners.
  
  
  METHODS
  A prospective, longitudinal study.
  
  
  METHODS
  HIV-1-seropositive IDU and their HIV-1-seronegative, non-IDU steady sex partners were recruited from six methadone-maintenance clinics in the New York City boroughs of Brooklyn and Manhattan.
  
  
  METHODS
  Between December 1988 and October 1991, 60 research participants were recruited [30 methadone-maintained, HIV-1-seropositive IDU (index subjects) and their non-IDU HIV-1-seronegative steady partners]. Baseline and follow-up (every 3-4 months) data included a structured questionnaire and blood testing for HIV infection and CD4+ cell subsets.
  
  
  RESULTS
  Demographic characteristics of the 30 steady sex partners were evaluated as follows: sex (22 women, eight men); age (mean, 32 years; range, 21-55 years) and race (African-American, 13; Hispanic, 13; other, 4). The average duration of relationship between index subject and partner at study entry was 7.5 years (range, 4 months to 19.4 years). At entry, 27 of the 30 partners reported no or intermittent use of condoms with the index subject during a typical 12-month period. Follow-up data (median follow-up, 298 days; range, 85-992 days) were available for 22 partners. Of these, 15 reported no or intermittent condom use. For a total study observation time of 23 person-years, there were no seroconversions. The upper 95% confidence interval for the observed seroconversion rate of 0% is 13%.
  
  
  CONCLUSIONS
  These results suggest that the likelihood of heterosexual HIV-1 transmission from seropositive methadone-maintained IDU to their seronegative, non-IDU steady sex partners is low.
authors: Division of Medical Services, Evaluation and Research Addiction Research and Treatment Corporation, Brooklyn, New York.
authors: N S
authors: NS
authors: Siddiqui
authors: L S
authors: LS
authors: Brown
authors: R Y
authors: RY
authors: Phillips
authors: O
authors: O
authors: Vargas
authors: R W
authors: RW
authors: Makuch
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000097:blood; D006679:HIV Seropositivity / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D011446:Prospective Studies; D012725:Sexual Behavior; D015819:Substance Abuse, Intravenous / Q000188:drug therapy; D011795:Surveys and Questionnaires; D016176:T-Lymphocyte Subsets
chemical_list: D015483:HIV Antibodies; D008691:Methadone